The treatment of metastatic castration-resistant prostate cancer has evolved since the approval of docetaxel-based therapy.
Since docetaxel approval, three new agents have gained approval for this indication: sipuleucel-T, cabazitaxel, and abiraterone. Recent Phase III trials have also demonstrated survival benefits for MDV-3100 and radium-223 though regulatory approval ispending. Practicing physicians face the challenge of determining the optimal sequencing of these new agents. This dilemma is particularly relevant to the post-docetaxel setting, in which the indication for several of these agents overlaps. This article details the efficacy and safety of these agents to provide a framework for their clinical use.
Written by:
Pal SK, Lewis B, Sartor O. Are you the author?
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):583-91.
doi: 10.1016/j.ucl.2012.07.013
PubMed Abstract
PMID: 23084533
